Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

Eloralintide vs Cagrilintide: Structure, Selectivity, PK and How to Tell Them Apart (2026)

By SaiyanMed Research Team · Updated 29 October 2026 · For in-vitro research use only

Three-panel illustration: an eloralintide-like peptide chain with a magnified methylene thioacetal ring bridge and a mid-chain lipid tail, a cagrilintide-like chain with a magnified disulfide bridge and an N-terminal lipid tail, and receptor complexes in a membrane.

Quick answer

Eloralintide (LY3841136, Eli Lilly) and cagrilintide (AM833 / NN0174-0833, Novo Nordisk) are both lipidated, 37-residue analogues of human amylin, but they are different molecules in four measurable ways. (1) Ring bridge: eloralintide closes Cys2–Cys7 with a carbon-containing methylene thioacetal (S–CH2–S); cagrilintide keeps a native disulfide (S–S). (2) Lipid position: eloralintide carries its C20 diacid on Lys26 in the middle of the chain; cagrilintide carries its C20 diacid on the N-terminal Lys1. (3) Receptor profile: in the published cAMP assays eloralintide is about 12-fold more potent at the human AMY1 receptor than at the calcitonin receptor (CTR), while cagrilintide is a non-selective amylin/calcitonin receptor agonist. (4) Mass and charge: eloralintide (C201H319N49O65S2, monoisotopic 4523.2604 Da) is about 117.01 Da heavier than cagrilintide (C194H312N54O59S2, 4406.2515 Da), and by our calculation it carries roughly −3 net charge at pH 7 versus roughly neutral for cagrilintide.[1][2][4][9] That mass gap, plus a simple reduction test described below, is enough to tell them apart in any laboratory with LC-MS.

Key takeaways

  • Not the same compound, not interchangeable. Different sponsors, sequences, ring chemistry, lipid site and receptor profile.[1][2][4]
  • Selectivity is relative, not absolute. Eloralintide is AMY1R-preferring (about 12× over CTR and 11× over AMY3R in human cAMP assays), not “CTR-free”. Its rat selectivity pattern differs from the human pattern.[4]
  • Half-life (published, human): eloralintide terminal t½ about 310–366 h (≈13–15 days) after single doses; cagrilintide about 159–195 h (≈7–8 days).[4][12]
  • Calculated identity markers: Δ mass 117.009 Da (mono), [M+4H]4+ m/z 1131.822 vs 1102.570, and the most abundant isotope peak at M+2 for both. Values labelled “calculated” are our own arithmetic from the registered formulas.
  • Development status (29 Oct 2026): eloralintide is in phase 3 (ENLIGHTEN programme); a cagrilintide–semaglutide combination is under FDA review; neither molecule is approved.[21][24][25]
  • No head-to-head human trial exists. The only direct comparisons are in vitro and in rats.[4][7]

Contents

  1. Identity card: the two molecules side by side
  2. Structure: residue-by-residue map
  3. Mechanism: AMY1R, AMY3R, CTR and RAMPs
  4. Selectivity data, read carefully
  5. Pharmacokinetics as published
  6. Clinical programmes as published
  7. How they sit in the amylin class
  8. Calculated analytical values
  9. How to tell them apart in the lab
  10. COA checklist and red flags
  11. Myths vs evidence
  12. Glossary
  13. FAQ
  14. References

Identity card: the two molecules side by side

Property Eloralintide Cagrilintide Source
Developer codes LY3841136 AM833; NN0174-0833 [1][2][4]
Key patent family US 2022/0288168 A1 (long-acting amylin receptor agonists) Novo Nordisk filings (see Kruse 2021) [17][8]
CAS 2883634-40-8 1415456-99-3 [1][2]
Molecular formula C201H319N49O65S2 C194H312N54O59S2 [1][3][2]
Monoisotopic mass 4523.2604 Da 4406.2515 Da [1][2]
Average MW 4526.11 g/mol ≈4409 g/mol [1][2]
Main chain 37 residues, C-terminal Tyr-NH2 37 residues, C-terminal Pro-NH2 [1][2][4]
Non-coded residues Pos. 11 ornithine, 15 α-methyl-Phe, 22 N-methyl-Asn; N-terminal γ-linked Glu None in the backbone [1][4]
Cys2–Cys7 bridge Methylene thioacetal (S–CH2–S) Disulfide (S–S) [4][2]
Lipid C20 diacid–γGlu–γGlu on Lys26 side chain C20 diacid–γGlu on Lys1 Nα [4][2][8]
Receptor profile AMY1R-preferring (human) Non-selective AMY1/2/3R + CTR [4][9][10]
Human terminal t½ ≈310–366 h (single dose) ≈159–195 h [4][12]
Net charge at pH 7 (calculated) ≈ −3 ≈ 0 to +0.3 Calculated
Estimated pI (calculated) ≈ 3.3 ≈ 8.6 Calculated
Table 1. Identity card. Calculated rows use a standard pKa set (see the calculations section) and are estimates, not measured values.

Two corrections to common online summaries are built into this table. First, the eloralintide ring is a thioacetal (two sulfurs bridged by one carbon), not a “thioether” (one sulfur, as in lanthionine or carba-bridged analogues).[4][16] Second, cagrilintide’s lipid is not on a side-chain lysine in the middle of the peptide: it is attached at the very N-terminus, on the α-amine of Lys1, which is why its sequence is often written with a leading “X”.[2][8]

Structure: residue-by-residue map

Side-by-side bead diagrams of two 37-residue amylin analog chains with modified positions highlighted, contrasting a mid-chain lipidated lysine and carbon-bridged ring with an N-terminal lipid and a direct sulfur–sulfur ring.
Schematic only. Bead positions are illustrative; use the sequence table below for exact residues.

Both molecules start from the 37-residue human amylin template (KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY-NH2), which aggregates readily in solution. Each sponsor solved that problem differently. Cagrilintide inherits the three proline substitutions of pramlintide (A25P, S28P, S29P), which reduce β-sheet aggregation, and adds N14E, V17R and Y37P plus the N-terminal lipid.[8][11] Eloralintide also uses the 25/28/29 prolines but goes further with backbone and side-chain changes and a non-reducible ring.[1][4]

Position Human amylin Eloralintide Cagrilintide
1 Lys γ-linked Glu (N-terminal) Lys, Nα-acylated with C20 diacid–γGlu
2–7 Cys…Cys (S–S) Cys…Cys (S–CH2–S) Cys…Cys (S–S)
10 Gln Gly Gln
11 Arg Ornithine Arg
14 Asn Glu Glu
15 Phe α-methyl-Phe Phe
17 Val Val Arg
18 His Arg His
22 Asn N-methyl-Asn Asn
25 Ala Pro Pro
26 Ile Lys, side chain acylated (C20 diacid–γGlu–γGlu) Ile
28 / 29 Ser / Ser Pro / Pro Pro / Pro
31 Asn Glu Asn
37 Tyr-NH2 Tyr-NH2 Pro-NH2
Table 2. Positions that differ from human amylin. Eloralintide differs at 12 positions plus the bridge chemistry; cagrilintide at 6 positions plus the lipid. Sequences from KEGG D12886 and PubChem CID 171397054; aligned by our own comparison.

Why the thioacetal matters for analysts. A methylene thioacetal inserts a single CH2 between the two sulfur atoms. It keeps the geometry of the original ring but cannot be cut by reducing agents such as DTT or TCEP, and it resists thiol–disulfide exchange.[16][4] Cagrilintide’s disulfide can be reduced. That difference gives a quick, orthogonal identity test (see verification).

Why the lipid site matters. Both lipids are C20 diacids designed to bind serum albumin and extend circulating half-life.[4][8] Eloralintide’s lipid sits on Lys26 through a two-γGlu linker, with three free carboxylates in the linker and diacid. Cagrilintide’s lipid sits at the N-terminus through one γGlu. The different charge, position and linker length change chromatographic retention and albumin binding, which is one reason published potencies are measured with and without human serum albumin.[4]

Mechanism: AMY1R, AMY3R, CTR and RAMPs

Amylin does not have a single dedicated receptor. Its receptors are built from the calcitonin receptor (CTR, a class B GPCR) paired with one of three receptor activity-modifying proteins (RAMP1, 2 or 3).[11] The combinations are:

  • CTR alone: the calcitonin receptor, which binds calcitonin strongly and amylin more weakly.[11]
  • AMY1R = CTR + RAMP1: high amylin affinity; also responds to CGRP.[11]
  • AMY2R = CTR + RAMP2: the least characterised amylin receptor.[11]
  • AMY3R = CTR + RAMP3: high amylin affinity.[11]

All four share the same CTR core, so “selectivity” in this family means relative preference, which depends on the RAMP context, the species and the assay. Cryo-EM structures show cagrilintide bound to CTR and to AMY1R, AMY2R and AMY3R, with very similar peptide poses across receptors. That is consistent with its non-selective profile.[10] Fletcher et al. characterised AM833 (cagrilintide) as a potent agonist across CTR and all three AMY receptors.[9] For eloralintide, Lilly’s design goal was to keep AMY1R potency while reducing CTR and AMY3R activity, on the hypothesis that AMY1R carries the appetite signal and broader activation contributes to nausea and taste aversion. That hypothesis is supported by rat data, not by a human comparison: in Lilly’s studies eloralintide produced less conditioned taste avoidance than cagrilintide (ED50 8.9 vs 4.2 nmol/kg), and in a diet-induced obese rat comparison fat accounted for about 80–91% of weight lost with eloralintide vs about 63% with cagrilintide.[4][7]

Some SERP pages describe eloralintide as having “minimal” or “no” calcitonin receptor activity. The primary data do not support that wording: it still activates human CTR at sub-nanomolar potency, only about an order of magnitude less potently than AMY1R.[4]

Selectivity data, read carefully

Assay (Briere 2025) Human AMY1R Human AMY3R Human CTR Fold CTR/AMY1R
cAMP EC50, eloralintide 23.9 pM 253.8 pM 291.0 pM ≈12×
Binding Ki, eloralintide 478.1 pM 3608.9 pM 3896.1 pM ≈8.1×
Table 3a. Human receptor data for eloralintide.[4] Fold values calculated from the reported means.
Assay (Briere 2025) Rat AMY1R Rat AMY3R Rat CTR Fold CTR/AMY1R
cAMP EC50, eloralintide 5.4 pM 13.8 pM 243.2 pM ≈45×
Binding Ki, eloralintide 48.1 pM 161.0 pM 5263.3 pM ≈109×
Table 3b. Rat receptor data.[4] In rat cells both AMY1R and AMY3R are strongly preferred over CTR, so rat selectivity is not the same as human selectivity.

Three points are easy to miss. (1) In the same assays cagrilintide showed comparable potency across AMY1R, AMY3R and CTR in both species, which is what “non-selective” means here.[4] (2) Eloralintide kept its preference when 1% human serum albumin was added, so albumin binding by the lipid does not erase the selectivity.[4] (3) Fold-selectivity in cAMP assays depends on receptor expression levels. Values from one laboratory’s cell lines should not be compared directly with values from another paper (for example, Fletcher’s panel for cagrilintide).[4][9]

Pharmacokinetics as published

Parameter Eloralintide Cagrilintide
Terminal half-life (human) ≈310–366 h (≈12.9–15.3 days), single-ascending-dose study[4]; ≈14 days reported in the multiple-dose study[5] ≈159–195 h (≈6.6–8.1 days)[12]
tmax (human) ≈72–132 h[4] ≈24–72 h[12]
Accumulation behaviour Steady-state peak-to-trough ratio ≈1.28–1.38[5] Reported in combination studies
Half-life driver C20 diacid albumin binding; non-reducible ring; protease-resistant residues C20 diacid albumin binding; proline substitutions
Table 4. Published human PK. Values are summarised as reported. Units are converted to days by us.

Correction note. An earlier version of this article quoted “13.9–15.8 days” from the multiple-dose study. That range does not appear in the source. The single-dose study reports 310–366 h, and the multiple-dose paper reports approximately 14 days.[4][5] We have corrected the figure. The calculated takeaway is that eloralintide’s reported half-life is roughly double cagrilintide’s (≈14 vs ≈7 days, a calculated ratio of about 1.9–2.0).

Clinical programmes as published

Results below are reported as published by sponsor-run trials. They are given for scientific context only and are not claims about any SaiyanMed product, which is sold for in-vitro research only.

Eloralintide

  • Phase 1 (NCT05295940, 148 participants): single-ascending doses in 48 healthy participants, then a 12-week multiple-dose part in 100 participants with overweight or obesity. In the multiple-dose part, least-squares mean body-weight change ranged from −2.6% to −11.3% across cohorts. Gastrointestinal events were concentrated in the higher cohorts. Paracetamol-absorption tests showed early slowing of gastric emptying that faded by about day 80.[4][5][18]
  • Phase 2 (NCT06230523, 263 participants, 48 weeks, 46 US sites): mean body-weight change of −9.5% to −20.1% across active arms vs −0.4% with placebo (efficacy estimand), or −7.3% to −17.5% vs −2.3% (treatment-regimen estimand). Nausea was reported in 11–64% of participants on active arms vs 14% on placebo. Serious adverse events: 5.3% vs 5.4%.[6][19]
  • Phase 2 with tirzepatide in type 2 diabetes (NCT06603571, 367 participants, 48 weeks): Lilly reported mean weight reduction of up to 23.3% with the combination vs 14.8% with tirzepatide alone. Discontinuation due to adverse events was 10.8–27.0% in combination arms, 0–10.8% with eloralintide alone, 2.9% with tirzepatide and 16.7% with placebo (company press release, EASD 2026; peer-reviewed paper pending).[20][23]
  • Phase 3 (ENLIGHTEN): as of 29 October 2026 the registry lists ENLIGHTEN-1 (no diabetes, ≈1,980 planned), -2 (type 2 diabetes), -3 (sleep apnoea), -4 (knee osteoarthritis pain), -6 (on background incretin) and -10 (type 2 diabetes with increased cardiovascular risk, not yet recruiting), plus two phase 3 combination studies with tirzepatide (AMPLIFY-1 and -2). No phase 3 results have been reported.[21][22][24]

Cagrilintide

  • Phase 2 monotherapy (n=706, 26 weeks): −6.0% to −10.8% vs −3.0% placebo.[13]
  • REDEFINE 1 (68 weeks): the cagrilintide-alone arm reached −11.8% (trial-product estimand) or −11.5% (treatment-policy) vs −2.3%/−3.0% placebo; the combination arm with semaglutide reached −22.7% / −20.4%. The often-quoted ≈20% figure belongs to the combination, not to cagrilintide alone.[14]
  • Regulatory status: Novo Nordisk filed the cagrilintide–semaglutide combination with the FDA in December 2025; as of this update no decision has been announced. Cagrilintide monotherapy is in its own phase 3 programme (RENEW).[25][24]

Why the numbers cannot be compared directly. Different trials, populations, durations (26, 48 or 68 weeks), estimands, titration schemes and placebo responses. No randomised human trial compares eloralintide with cagrilintide. Any article that ranks one above the other from these figures is doing a cross-trial comparison the evidence does not support.

How they sit in the amylin class

Agent Developer Class label used in reviews Receptor emphasis Dosing interval studied Stage (latest public)
Pramlintide AstraZeneca (originally Amylin) Short-acting amylin analogue AMY1/2/3R Multiple daily Approved (diabetes)
Cagrilintide Novo Nordisk Long-acting DACRA AMY1/2/3R + CTR Weekly Phase 3; combination under FDA review
Eloralintide Eli Lilly Selective amylin receptor agonist AMY1R-preferring Weekly Phase 3
Petrelintide Zealand / Roche Long-acting DACRA AMY3R and CTR (per review) Weekly Phase 2
ABBV-295 (GUBamy) AbbVie / Gubra Long-acting DACRA Not fully disclosed Weekly to monthly Phase 1
MET-233i Metsera (Pfizer) Ultra-long-acting amylin analogue Not fully disclosed Weekly, monthly intent Phase 1
AZD6234 AstraZeneca Selective amylin receptor agonist AMY3R (per review) Not fully disclosed Phase 1
Amycretin (zenagamtide) Novo Nordisk Unimolecular GLP-1 + amylin agonist GLP-1R + AMY/CTR Weekly / oral daily Phase 3
Table 5. Amylin-pathway agents in clinical development. Class labels and receptor emphasis follow the 2026 Alhazmi & le Roux review; stages are approximate and change often.[15]

The class splits into two design philosophies. DACRAs (dual amylin and calcitonin receptor agonists) such as cagrilintide and petrelintide deliberately engage CTR. Selective agonists such as eloralintide and AZD6234 try to avoid it. There is no human head-to-head data yet showing which approach is better. The review notes possible secondary roles for CTR activation (for example in bone), as well as tolerability trade-offs.[15] Incretin agents (semaglutide: GLP-1R; tirzepatide: GIPR + GLP-1R) act on a different receptor family and are being combined with amylin agents rather than replaced by them.[14][23]

Calculated analytical values

Everything in this section is calculated by the SaiyanMed Research Team from the registered molecular formulas (KEGG D12886 and PubChem CID 171397054), using IUPAC monoisotopic masses, a proton mass of 1.007276 Da and natural isotope abundances. We rebuilt both formulas from the residue-level structure and reproduced the registry formulas exactly. Instrument calibration, adducts and salt forms will shift observed values.

Ion Eloralintide m/z (calculated) Cagrilintide m/z (calculated) Δ m/z
[M+2H]2+ 2262.638 2204.133 58.50
[M+3H]3+ 1508.761 1469.758 39.00
[M+4H]4+ 1131.822 1102.570 29.25
[M+5H]5+ 905.659 882.258 23.40
[M+6H]6+ 754.884 735.383 19.50
Table 6. Calculated monoisotopic m/z for protonated ions. Most ESI instruments will show the 3+ to 5+ states most strongly for peptides of this size. Neutral monoisotopic Δ = 117.009 Da; average-mass Δ ≈ 117.09 Da (calculated).
Isotope peak M M+1 M+2 M+3 M+4 M+5
Eloralintide (relative %) 31.6 76.8 100 91.8 66.2 39.8
Cagrilintide (relative %) 33.3 78.8 100 89.4 62.8 36.7
Table 7. Calculated isotope envelopes. For both peptides the tallest peak is M+2, not the monoisotopic peak, so deconvolution software that reports the ‘most abundant’ mass will read about 2 Da above the monoisotopic value.
Two schematic mass spectra with isotope envelopes at different positions, each magnified, illustrating that eloralintide and cagrilintide are separated by about 117 Da in intact mass.
Schematic. Calculated separation: 117.01 Da monoisotopic, ≈117.1 Da average.
Quantity Eloralintide Cagrilintide
Molar amount per mg of free peptide (calculated) ≈0.221 µmol (221 nmol) ≈0.227 µmol (227 nmol)
MW + 1 acetate (calculated) ≈4586.2 ≈4469.1
MW + 3 acetate (calculated) ≈4706.3 ≈4589.2
MW + 1 TFA (calculated) ≈4640.1 ≈4523.0
MW + 3 TFA (calculated) ≈4868.2 ≈4751.1
Net charge pH 4 / 7 / 8 (calculated) ≈ −0.9 / −3.0 / −3.2 ≈ +2.5 / +0.3 / 0.0
Table 8. Molar and counter-ion arithmetic. Each acetate adds 60.05 Da and each trifluoroacetate 114.02 Da. Net peptide content on a COA (often 70–90% for lyophilised peptides) must be applied before any molar calculation.

Note one coincidence in Table 8: cagrilintide with one TFA counter-ion (≈4523.0) has nearly the same average mass as free eloralintide (4526.1). This only matters for low-resolution or average-mass readouts, but it is a reason to report monoisotopic or charge-state data rather than a single “MW found” number. The charge estimates (EMBOSS-type pKa values; α-carboxyl of N-terminal γGlu ≈2.2; C20 diacid ≈4.6; His 6.5) also explain a detail in the discovery paper: eloralintide was formulated in a pH 8 buffer and cagrilintide in a pH 4 buffer.[4] By our calculation that places each peptide well away from its estimated isoelectric point (≈3.3 and ≈8.6), where solubility is lowest. This interpretation is ours, not the authors’.

How to tell them apart in the lab

  • Intact LC-MS (primary test). Match the deconvoluted monoisotopic mass to 4523.26 (eloralintide) or 4406.25 (cagrilintide) within the instrument’s stated accuracy, and check at least two charge states against Table 6. A 117 Da offset identifies the wrong peptide; offsets of +60/+114 Da suggest acetate/TFA adducts; +22/+38 Da suggest Na/K adducts; +16 Da suggests oxidation (neither sequence contains Met or Trp, so ring sulfur, Tyr or His are the usual candidates); +1 Da suggests deamidation of Asn.
  • Reduction test (orthogonal, calculated shift). Treat an aliquot with DTT or TCEP and re-run LC-MS. Cagrilintide’s disulfide reduces, giving +2.016 Da (calculated) and usually a retention-time change. Eloralintide’s methylene thioacetal does not reduce, so its mass is unchanged.[16] This is the cleanest way to distinguish the two ring chemistries.
  • RP-HPLC purity. Both are lipidated and elute late on C18/C8 columns under acidic gradients. Use the supplier’s method, or a shallow acetonitrile/0.1% TFA gradient at elevated column temperature, and report main-peak area %. Retention time alone is not identity. Spiking with an authentic reference is the confirmatory step.
  • MS/MS sequence tags (optional). Fragmentation around the Pro-rich C-terminal region (…LPPTNVGSNTP for cagrilintide vs …LPPTEVGSNTY for eloralintide) gives distinguishing b/y ions. The modified residues in eloralintide (Orn, α-Me-Phe, N-Me-Asn) produce residue masses not found in coded amino acids.
  • Peptide content. Amino-acid analysis or nitrogen content plus counter-ion assay (ion chromatography for acetate/TFA) to convert “mg of powder” into “nmol of peptide”.[4]

Troubleshooting decision path

  1. Observed mass ≈4523 → consistent with eloralintide; confirm with charge states and a reduction test showing no shift.
  2. Observed mass ≈4406 → consistent with cagrilintide; reduction should give +2 Da.
  3. Observed mass ≈4523 but reduction shifts +2 Da → not eloralintide. Check for cagrilintide + TFA or another analogue.
  4. Observed ≈4526 average only, no isotope resolution → ambiguous; request high-resolution data.
  5. Mass 2–3 Da off the monoisotopic value → check whether the software reported the most-abundant (M+2) peak.
  6. Multiple peaks 60 or 114 Da apart → counter-ion adducts; compare against the stated salt form.

COA checklist and red flags

  • Name, CAS and molecular formula match Table 1 (eloralintide CAS 2883634-40-8; cagrilintide CAS 1415456-99-3).[1][2]
  • Mass spectrum attached as an image or trace, not just a typed number, with the observed charge states.
  • HPLC chromatogram with method conditions (column, gradient, wavelength) and integrated purity.
  • Salt form and net peptide content stated.
  • Batch/lot number matching the vial label, test date and the name of the testing laboratory.
  • For more on reading these documents, see our guides How to read a peptide COA and What mass spectrometry can and cannot confirm.

Red flags: an “eloralintide” COA that reports MW ≈4409 or quotes a disulfide bond; a “cagrilintide” COA with MW ≈4526; molecular weights given without a spectrum; identical chromatograms reused across different peptides; formulas that do not match the registry; or purity stated with no method.

Myths vs evidence

Claim seen online What the primary evidence shows
“Eloralintide has no calcitonin receptor activity.” It activates human CTR at ≈291 pM in cAMP assays, about 12× weaker than AMY1R. Preferring is not excluding.[4]
“Eloralintide has a thioether bridge.” It is a methylene thioacetal: S–CH2–S, two sulfurs plus one carbon.[4][16]
“Cagrilintide alone gives ≈20% weight loss.” ≈20% is the cagrilintide–semaglutide combination in REDEFINE 1; the cagrilintide-alone arm was ≈11.5–11.8%.[14]
“No half-life has been measured for eloralintide.” Terminal t½ ≈310–366 h was reported in the single-dose study.[4]
“Eloralintide is proven better tolerated than cagrilintide.” Less conditioned taste avoidance was shown in rats; no human head-to-head study exists.[4][7]
“They are the same molecule from different labs.” Different sequences at multiple positions, ring chemistry, lipid site, formula and mass (Δ≈117 Da).[1][2]
“Eloralintide is approved.” No. It is in phase 3 as of 29 October 2026.[21][24]
Table 9. Myths vs evidence.

Glossary

  • Amylin: a 37-residue peptide hormone co-secreted with insulin by pancreatic β-cells.
  • AMY1R / AMY2R / AMY3R: amylin receptors formed by the calcitonin receptor plus RAMP1, RAMP2 or RAMP3.
  • CTR: calcitonin receptor, a class B G protein-coupled receptor.
  • RAMP: receptor activity-modifying protein; changes which ligands a receptor prefers.
  • DACRA: dual amylin and calcitonin receptor agonist.
  • Methylene thioacetal: an S–CH2–S bridge used as a non-reducible disulfide replacement.
  • C20 diacid: a 20-carbon fatty diacid attached to extend half-life through albumin binding.
  • γGlu linker: glutamic acid linked through its side-chain (γ) carboxyl, used to connect the lipid.
  • EC50 / Ki: concentration giving half-maximal response / binding inhibition constant.
  • Monoisotopic mass: mass calculated with only the most abundant isotope of each element.
  • Estimand: the precise definition of the treatment effect a trial estimates (for example, efficacy vs treatment-regimen).
  • RUO: research use only; not for human or veterinary use.

Frequently asked questions

What is the difference between eloralintide and cagrilintide?

Both are long-acting, lipidated amylin analogues, but eloralintide (Eli Lilly) uses a methylene thioacetal ring and a lipid on Lys26 and prefers the AMY1 receptor, while cagrilintide (Novo Nordisk) keeps a disulfide ring and an N-terminal lipid and activates amylin and calcitonin receptors non-selectively. Their monoisotopic masses differ by about 117 Da (calculated).

Is eloralintide selective for amylin receptors?

It is AMY1R-preferring. In human cell assays it was about 12-fold more potent at AMY1R than at CTR and about 11-fold more potent than at AMY3R. It is not inactive at the calcitonin receptor.

What is the half-life of eloralintide?

In the published single-dose phase 1 study, the terminal half-life was about 310–366 hours (roughly 13–15 days). The multiple-dose study reported approximately 14 days. Cagrilintide’s reported half-life is about 159–195 hours.

What is the molecular weight of eloralintide?

Eloralintide is C201H319N49O65S2, with an average molecular weight of 4526.11 g/mol and a monoisotopic mass of 4523.2604 Da (KEGG D12886).

What is the molecular weight of cagrilintide?

Cagrilintide is C194H312N54O59S2, with an average molecular weight of about 4409 g/mol and a monoisotopic mass of 4406.2515 Da (PubChem CID 171397054).

How can a lab tell eloralintide and cagrilintide apart?

Use intact LC-MS: the calculated monoisotopic masses differ by 117.009 Da, and the [M+4H]4+ ions fall at about m/z 1131.82 vs 1102.57. As an orthogonal check, DTT or TCEP reduction shifts cagrilintide by +2 Da but leaves eloralintide unchanged, because its thioacetal ring cannot be reduced.

Is eloralintide FDA approved?

No. As of 29 October 2026, eloralintide is investigational and in phase 3 trials (the ENLIGHTEN programme). It is not approved by the FDA or any other regulator.

Has eloralintide been compared head-to-head with cagrilintide in humans?

No. The only direct comparisons are in vitro receptor assays and rat studies in Lilly’s discovery work. Results from separate human trials cannot be compared directly.

Is cagrilintide the same as CagriSema?

No. Cagrilintide is the amylin analogue alone. The combination product pairs cagrilintide with semaglutide, and most of the widely quoted ≈20% figures refer to that combination.

Why is eloralintide called an amylin analogue if it has non-natural amino acids?

Its 37-residue backbone follows the human amylin template and targets amylin receptors. The non-coded residues (ornithine, α-methyl-phenylalanine, N-methyl-asparagine) and the thioacetal ring were added to improve stability and reduce aggregation.

This page stays on the same receptor family (two amylin analogs). For how an AMY1R-preferring amylin agonist differs mechanistically from a GLP-1/GIP/glucagon triple agonist in published research designs—without treating separate trials as head-to-head—see eloralintide vs retatrutide.

Related reading

About the authors

SaiyanMed Research Team. This article was written and fact-checked by the SaiyanMed Research Team from primary sources: peer-reviewed papers, trial registries, patent filings and the KEGG and PubChem registries. Calculated values were computed in-house and are labelled as such. Sources were last checked on 29 October 2026. Read how we document testing in our Trust Center.

References

  1. KEGG DRUG D12886: Eloralintide (USAN). Formula C201H319N49O65S2, exact mass 4523.2604, CAS 2883634-40-8
  2. PubChem CID 171397054: Cagrilintide. C194H312N54O59S2, CAS 1415456-99-3
  3. PubChem CID 497621299: Eloralintide
  4. Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. Mol Metab 2025;102:102271
  5. Bhattachar SN, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: phase 1 proof of concept. Diabetes Obes Metab 2026;28(4):2651–2660
  6. Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2025;406:2631–2643
  7. Briere DA, et al. 849-P: Eloralintide (LY3841136), a selective amylin mimetic, lowered body weight with improved quality of weight loss and GI tolerability in rats compared with cagrilintide. Diabetes 2025;74(Suppl 1)
  8. Kruse T, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem 2021;64:11183–11194
  9. Fletcher MM, et al. AM833 is a novel agonist of calcitonin family G protein–coupled receptors: pharmacological comparison with six selective and nonselective agonists. J Pharmacol Exp Ther 2021;377:417–440
  10. Cao J, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nat Commun 2025;16
  11. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev 2015;67:564–600
  12. Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management. Lancet 2021;397:1736–1748
  13. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021;398:2160–2172
  14. Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med 2025;393:635–647
  15. Alhazmi A, le Roux CW. Amylin analogs: the next major class of weight loss therapy. A review of experimental data and early-phase clinical trials. Diabetes Obes Metab 2026;28
  16. Zhou et al. Strategic applications of methylene thioacetal bonds as disulfide surrogates in peptide drug discovery. Front Chem 2025
  17. US 2022/0288168 A1. Long acting amylin receptor agonists and uses thereof (Eli Lilly and Co)
  18. ClinicalTrials.gov NCT05295940: phase 1 SAD/MAD study of LY3841136 (148 participants, completed)
  19. ClinicalTrials.gov NCT06230523: phase 2 study of LY3841136 vs placebo (263 participants, completed)
  20. ClinicalTrials.gov NCT06603571: phase 2 study of LY3841136 and tirzepatide, alone or combined, in type 2 diabetes (367 participants, completed)
  21. ClinicalTrials.gov NCT07321886: ENLIGHTEN-1, phase 3 (obesity or overweight without type 2 diabetes)
  22. ClinicalTrials.gov NCT07282600: ENLIGHTEN-2, phase 3 (with type 2 diabetes)
  23. Eli Lilly and Company press release, 30 September 2026: phase 2b results of eloralintide plus tirzepatide in obesity with type 2 diabetes (EASD 2026)
  24. ClinicalTrials.gov search: intervention = eloralintide (registry checked 29 October 2026)
  25. Novo Nordisk press release, 18 December 2025: FDA submission for the cagrilintide–semaglutide combination

Research Use Only Disclaimer

This article is for laboratory and analytical education only. All SaiyanMed products are sold strictly for in-vitro research use only (RUO). They are not drugs, foods, supplements or cosmetics and are not for human or animal use. Nothing here is medical advice, a protocol for administration, or a claim about any effect. Clinical-trial results are summarised as published findings from sponsor-run studies, for scientific context only. Eloralintide and cagrilintide are investigational and not approved by the FDA or any other regulator as of the date of this article.

{“@context”: “https://schema.org”, “@type”: “FAQPage”, “@id”: “https://saiyanmed.com/eloralintide-vs-cagrilintide/#faq”, “mainEntity”: [{“@type”: “Question”, “name”: “What is the difference between eloralintide and cagrilintide?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Both are long-acting, lipidated amylin analogues, but eloralintide (Eli Lilly) uses a methylene thioacetal ring and a lipid on Lys26 and prefers the AMY1 receptor, while cagrilintide (Novo Nordisk) keeps a disulfide ring and an N-terminal lipid and activates amylin and calcitonin receptors non-selectively. Their monoisotopic masses differ by about 117 Da (calculated).”}}, {“@type”: “Question”, “name”: “Is eloralintide selective for amylin receptors?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “It is AMY1R-preferring. In human cell assays it was about 12-fold more potent at AMY1R than at CTR and about 11-fold more potent than at AMY3R. It is not inactive at the calcitonin receptor.”}}, {“@type”: “Question”, “name”: “What is the half-life of eloralintide?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “In the published single-dose phase 1 study, the terminal half-life was about 310–366 hours (roughly 13–15 days). The multiple-dose study reported approximately 14 days. Cagrilintide’s reported half-life is about 159–195 hours.”}}, {“@type”: “Question”, “name”: “What is the molecular weight of eloralintide?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Eloralintide is C201H319N49O65S2, with an average molecular weight of 4526.11 g/mol and a monoisotopic mass of 4523.2604 Da (KEGG D12886).”}}, {“@type”: “Question”, “name”: “What is the molecular weight of cagrilintide?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Cagrilintide is C194H312N54O59S2, with an average molecular weight of about 4409 g/mol and a monoisotopic mass of 4406.2515 Da (PubChem CID 171397054).”}}, {“@type”: “Question”, “name”: “How can a lab tell eloralintide and cagrilintide apart?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Use intact LC-MS: the calculated monoisotopic masses differ by 117.009 Da, and the [M+4H]4+ ions fall at about m/z 1131.82 vs 1102.57. As an orthogonal check, DTT or TCEP reduction shifts cagrilintide by +2 Da but leaves eloralintide unchanged, because its thioacetal ring cannot be reduced.”}}, {“@type”: “Question”, “name”: “Is eloralintide FDA approved?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “No. As of 29 October 2026, eloralintide is investigational and in phase 3 trials (the ENLIGHTEN programme). It is not approved by the FDA or any other regulator.”}}, {“@type”: “Question”, “name”: “Has eloralintide been compared head-to-head with cagrilintide in humans?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “No. The only direct comparisons are in vitro receptor assays and rat studies in Lilly’s discovery work. Results from separate human trials cannot be compared directly.”}}, {“@type”: “Question”, “name”: “Is cagrilintide the same as CagriSema?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “No. Cagrilintide is the amylin analogue alone. The combination product pairs cagrilintide with semaglutide, and most of the widely quoted ≈20% figures refer to that combination.”}}, {“@type”: “Question”, “name”: “Why is eloralintide called an amylin analogue if it has non-natural amino acids?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Its 37-residue backbone follows the human amylin template and targets amylin receptors. The non-coded residues (ornithine, α-methyl-phenylalanine, N-methyl-asparagine) and the thioacetal ring were added to improve stability and reduce aggregation.”}}]}